Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis

Abstract

Objective To systematically review longitudinal studies evaluating use of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and risk of pneumonia.Design Systematic review and meta-analysis.Data sources Medline through PubMed, Web of Science with conference proceedings (inception to June 2011), and US Food and Drug Administration website (June 2011). Systematic reviews and references of retrieved articles were also searched.Study selection Two reviewers independently selected randomised controlled trials and cohort and case-control studies evaluating the use of ACE inhibitors or ARBs and risk of pneumonia and retrieved characteristics of the studies and data estimates.Data synthesis The primary outcome was incidence of pneumonia and the secondary outcome was pneumonia related mortality. Subgroup analyses were carried according to baseline morbidities (stroke, heart failure, and chronic kidney disease) and patients' characteristics (Asian and non-Asian). Pooled estimates of odds ratios and 95% confidence intervals were derived by random effects meta-analysis. Adjusted frequentist indirect comparisons between ACE inhibitors and ARBs were estimated and combined with direct evidence whenever available. Heterogeneity was assessed using the I 2 test.Results 37 eligible studies were included. ACE inhibitors were associated with a significantly reduced risk of pneumonia compared with control treatment (19 studies: odds ratio 0.66, 95% confidence interval 0.55 to 0.80; I 2 =79%) and ARBs (combined direct and indirect odds ratio estimate 0.69, 0.56 to 0.85). In patients with stroke, the risk of pneumonia was also lower in those treated with ACE inhibitors compared with control treatment (odds ratio 0.46, 0.34 to 0.62) and ARBs (0.42, 0.22 to 0.80). ACE inhibitors were associated with a significantly reduced risk of pneumonia among Asian patients (0.43, 0.34 to 0.54) compared with non-Asian patients (0.82, 0.67 to 1.00; P<0.001). Compared with control treatments, both ACE inhibitors (seven studies: odds ratio 0.73, 0.58 to 0.92; I 2 =51%) and ARBs (one randomised controlled trial: 0.63, 0.40 to 1.00) were associated with a decrease in pneumonia related mortality, without differences between interventions. ConclusionsThe best evidence available points towards a putative protective role of ACE inhibitors but not ARBs in risk of pneumonia. Patient populations that may benefit most are those with previous stroke and Asian patients. ACE inhibitors were also associated with a decrease in pneumonia related mortality, but the data lacked strength. IntroductionPneumonia represents an important clinical condition because of its relatively high incidence (0.5% to 1.1% annually in the United Kingdom) and associated morbidity and mortality. Susceptibility is higher among elderly people (≥65 years), those with alcohol dependency, smokers, and patients with heart failure, previous stroke, diabetes, chronic kidney disease, and chronic lung disease. [3][4][5][6] Pneumonia is a common reason for h...

Increase of Substance P Concentration in Saliva after Pharyngeal Electrical Stimulation in Severely Dysphagic Stroke Patients – an Indicator of Decannulation Success?

“…Consequently, referring to the ability of SP to enhance protective reflexes, ACE inhibitor treatment has been discussed as a possible strategy to reduce aspiration after stroke [47]. Interestingly, in line with this reasoning, two Asian observational studies found reduced pneumonia rates in hypertensive stroke patients treated with ACE inhibitors in comparison to patients managed with other antihypertensive drugs [48, 49], a conclusion that was also uphold in a meta-analysis [50, 51]. However, in more recent trials, this assumption was decisively questioned with two case-control studies and one randomized-controlled trial failing to show any evidence of a putative protective role of ACE inhibitors in dysphagic stroke and non-stroke patients [52-54].…”

Sources of heterogeneity in case–control studies on associations between statins, ACE-inhibitors, and proton pump inhibitors and risk of pneumonia

“…Proposed mechanisms of action behind these associations are interference with aspiration and cough induction through ACE inhibition [3], immunomodulation by statins, and gastrointestinal bacteria overgrowth due to increased stomach pH by proton pump inhibition. Recent reviews and meta-analyses of ACEi and CAP [4], statins and CAP [5,6], as well as PPI and CAP [7] show a marked heterogeneity in findings. In these reviews, the most often mentioned explanation for differences in findings is unmeasured confounding in some or all of the studies reviewed.…”

Novel Risk Score to Predict Pneumonia After Acute Ischemic Stroke

“…First, as all observational studies, we cannot rule out the possibility that additional baseline variable (unmeasured confounders) might have some impact on the development of in-hospital SAP after AIS, such as use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. 44 Second, the time course of SAP after AIS is unclear. Because we only have information on new-onset SAP during hospitalization without documentation of the exact date, our data allow no conclusion as to whether patients with a longer length of stay per se are more likely to develop pneumonia or whether diagnosis of pneumonia leads to a longer hospitalization.…”